Exploring how Clusterin affects brain cell development in Alzheimer's disease

Understanding the impact of Clusterin on the oligodendrocyte lineage in AD

NIH-funded research University of Virginia · NIH-10539074

This study is looking at how a protein called Clusterin affects the brain cells that help repair myelin, which is important for brain health, in people with Alzheimer's disease, to find new ways to help improve memory and thinking skills.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionUniversity of Virginia NIH-funded
Lab location1 site (Charlottesville, United States)
Project IDNIH-10539074 on NIH RePORTER

What this research studies

This research investigates the role of Clusterin, a protein linked to Alzheimer's disease, in the development of oligodendrocyte progenitor cells (OPCs) that are crucial for myelin repair in the brain. The study aims to understand why these cells fail to produce myelin in Alzheimer's patients, which is believed to contribute to cognitive decline. By examining the relationship between Clusterin levels and myelin disruption, the research seeks to uncover new insights that could lead to effective therapies for Alzheimer's disease. The approach includes using mouse models and analyzing genetic factors associated with the disease.

Who could benefit from this research

Good fit: Ideal candidates for this research are adults aged 21 and older who are diagnosed with Alzheimer's disease or exhibit early signs of cognitive decline.

Not a fit: Patients with other forms of dementia unrelated to Alzheimer's disease may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new therapeutic strategies that enhance myelin repair and improve cognitive function in Alzheimer's patients.

How similar studies have performed: While the specific role of Clusterin in OPCs and myelination in Alzheimer's has not been previously studied, related research has shown promising results in understanding myelin disruption in neurodegenerative diseases.

Where this research is happening

Charlottesville, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Alzheimer's DiseaseAlzheimer diseaseAlzheimer syndrome
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.